HFpEF – Medxy AI

Personalized Risk Modeling of Interatrial Shunt Therapy in Heart Failure: Insights from the RELIEVE-HF Trial

By MedXY 08/15/2026

The RELIEVE-HF trial reveals distinct predictors of outcomes after interatrial shunt implantation in HFrEF and HFpEF, enabling personalized risk modeling to identify patients likely to benefit from this therapy.

Cardiology news

Unveiling Heart Failure with Preserved Ejection Fraction in Adults with Congenital Heart Disease: Prevalence, Characteristics, and Clinical Challenges

By MedXY 08/12/2026

This article explores the high prevalence of heart failure with preserved ejection fraction (HFpEF) in adults with congenital heart disease (ACHD), highlighting its clinical features, hospitalization burden, and under-treatment issues.

Cardiology news Respiratory

Unveiling the Phenotype of Unclassified Pulmonary Hypertension: A Hidden Spectrum of Early Heart Failure with Preserved Ejection Fraction

By MedXY 06/20/2026

Unclassified pulmonary hypertension often reflects early-stage HFpEF linked to left heart and metabolic dysfunction, identifiable via dynamic right heart catheterization and metabolomics.

Cardiology Internal Medicine news

Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model

By MedXY 06/15/2026

Elamipretide improved skeletal muscle force, titin phosphorylation, and atrophy in a HFpEF rat model, supporting cardiolipin stabilization as a promising mitochondrial-targeted strategy.

Cardiology news

Elamipretide Restores Skeletal Muscle Performance in a HFpEF Rat Model by Stabilizing Mitochondria

By MedXY 06/15/2026

In a HFpEF rat model, Elamipretide improved muscle force, reduced titin abnormalities, and prevented atrophy, supporting cardiolipin stabilization as a potential strategy for exercise intolerance.

Cardiology Internal Medicine news

Can a Mitochondrial “Membrane Stabilizer” Restore Muscle Function in HFpEF? New Rat Data on Elamipretide

By MedXY 06/15/2026

In a HFpEF rat model, elamipretide improved skeletal muscle force, reduced titin hyperphosphorylation, and prevented atrophy, supporting cardiolipin stabilization as a promising metabolic strategy.

Cardiology news

Cardiolipin Stabilization Revives Skeletal Muscle Performance in a Preclinical HFpEF Model

By MedXY 06/15/2026

In a rat model of HFpEF, the mitochondrial-targeted peptide elamipretide improved skeletal muscle force, reduced atrophy, and normalized titin phosphorylation, supporting cardiolipin stabilization as a promising mechanism.

Cardiology Internal Medicine news

SRPK3-Driven TPM1 Splicing Emerges as a Myofilament Mechanism of Diastolic Dysfunction in HFpEF

By MedXY 06/09/2026

A Circulation study identifies SRPK3-mediated alternative splicing of TPM1 exon 9a as a driver of myofibrillar disarray, reduced myocardial compliance, and diastolic dysfunction in HFpEF, highlighting a potential disease-modifying therapeutic target.

Cardiology news

Validated EMPEROR-Preserved Risk Models Stratify Prognosis in FINEARTS-HF, While Finerenone Benefits Remain Consistent Across Baseline Risk

By MedXY 05/19/2026

In FINEARTS-HF, EMPEROR-Preserved biomarker-based risk models showed good prognostic discrimination in HFmrEF/HFpEF, and finerenone’s relative treatment effect was consistent across the full baseline risk spectrum.

Cardiology Internal Medicine news

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial

By MedXY 05/12/2026

In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.

Cardiology news

Exercise Unmasks Multi-Organ Deficits That Predict Heart Failure Risk: Metabolite Signatures Reveal Shared Pathways Across HFpEF and Its Comorbidities

By MedXY 04/15/2026

A landmark study reveals that exercise-induced multi-organ physiologic deficits strongly predict incident heart failure with preserved ejection fraction (HFpEF). Using invasive cardiopulmonary testing, metabolomics, and genomics across over 6,000 individuals, researchers identified seven distinct exercise deficits that, when combined, confer nearly 4-fold higher cardiovascular risk and implicate shared metabolic pathways with obesity, diabetes, and renal disease.

Cardiology news

Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity

By MedXY 01/17/2026

The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure and preserved ejection fraction.

Cardiology Internal Medicine news

Beyond Congestion: The Wet-Cold Phenotype Drives Mortality in Obese HFpEF

By MedXY 12/29/2025

A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting the need for precise hemodynamic profiling.

Cardiology Internal Medicine news

Beyond the Scale: Abdominal Adiposity Outperforms BMI in Predicting Outcomes for HFpEF and HFmrEF

By MedXY 12/26/2025

A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit excess abdominal adiposity, necessitating a shift in clinical assessment.

Cardiology Internal Medicine news

Rethinking Biomarker Thresholds: Why Current NT-proBNP Cutoffs Fail Patients with Obesity and HFpEF

By MedXY 12/26/2025

A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial eligibility cutoffs.

Cardiology Clinical Updates news

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone's efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and chronic obstructive pulmonary disease.

Cardiology news

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY 12/04/2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality.

Cardiology Clinical Updates news Specialties

Decline in LVEF Predicts Ventricular Tachyarrhythmias and Mortality in HFpEF: Insights from the CHART-2 Study

By MedXY 09/02/2025

A mild-to-significant decline in left ventricular ejection fraction (LVEF) in heart failure with preserved ejection fraction (HFpEF) signals higher risks of lethal arrhythmias, sudden cardiac death, and mortality, underscoring the need for ongoing LVEF monitoring.

Cardiology Clinical Updates news Specialties

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY 08/31/2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Cardiology Clinical Updates news Respiratory Specialties

Unraveling Heart-Lung Interactions in HFpEF: The Impact of Dynamic Hyperinflation on Exercise Pulmonary Capillary Wedge Pressure

By MedXY 08/24/2025

Exercise-induced dynamic hyperinflation in HFpEF patients is linked to elevated pulmonary capillary wedge pressure, suggesting altered lung mechanics contribute significantly to exercise intolerance beyond ventricular stiffness alone.